Eugia Pharma Specialities, a wholly-owned subsidiary of Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804), has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Dasatinib Tablets, according to a Wednesday filing to the Indian stock exchanges.
The drug is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company's reference listed drug Sprycel Tablets, which is indicated for treating chronic myelogenous leukemia and acute lymphoblastic leukemia.
The product is expected to be launched in the fiscal first quarter of financial year 2025-26.
The company's shares were up over 3% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。